Economic evaluation of treatments for chronic hepatitis B

Brazilian Journal of Infectious Diseases

Volumn 17, Issue 4, 2013, Pages 418-426

  Wiens, Astrid ^a   Lenzi, Luana ^a   Venson, Rafael ^a   Pedroso, Maria Lúcia Alves ^a   Correr, Cassyano Januário ^a   Pontarolo, Roberto ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Chronic hepatitis B; Economic evaluation; Treatments

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ENTECAVIR; LAMIVUDINE; PEGINTERFERON ALPHA; TELBIVUDINE; TENOFOVIR;

ARTICLE; BRAZIL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MEDICAL DECISION MAKING; RESOURCE ALLOCATION; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

CHRONIC HEPATITIS B; ECONOMIC EVALUATION; TREATMENTS;

ADENINE; ANTIVIRAL AGENTS; BRAZIL; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; MALE; MARKOV CHAINS; ORGANOPHOSPHONATES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS;

EID: 84880929154     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/j.bjid.2012.12.005     Document Type: Article

References (45)

1. Barcena Marugan R., Garcia Garzon S. DNA-guided hepatitis B treatment, viral load is essential, but not sufficient. World J Gastroenterol 2009, 15:423-430.
2. Elgouhari H.M., Abu-Rajab Tamimi T.I., Carey W.D. Hepatitis B virus infection: understanding its epidemiology, course, and diagnosis. Cleve Clin J Med 2008, 75:881-889.
3. Nguyen M.H., Keeffe E.B. Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides. J Viral Hepat 2009, 16:149-155.
4. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
5. Hunink M., Glasziou P. Decision making in health and medicine: integrating the evidence and values 2001, Cambridge University Press, London.
6. Chan H.L., Wang H., Niu J., Chim A.M., Sung J.J. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir Ther 2007, 12:345-353.
7. Chang T.T., Gish R.G., de Man R., Gadano A., Sollano J., Chao Y.C., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006, 354:1001-1010.
8. Gish R.G., Lok A.S., Chang T.T., de Man R.A., Gadano A., Sollano J., et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007, 133:1437-1444.
9. Leung N., Peng C.Y., Hann H.W., Sollano J., Lao-Tan J., Hsu C.W., et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 2009, 49:72-79.
10. Marcellin P., Chang T.T., Lim S.G., Tong M.J., Sievert W., Shiffman M.L., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003, 348:808-816.
11. Marcellin P., Heathcote E.J., Buti M., Gane E., de Man R.A., Krastev Z., et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008, 359:2442-2455.
12. Ayaz C., Celen M.K., Colak H., Hosoglu S., Geyik M.F. Comparison of lamivudine and alpha-interferon combination with alpha-interferon alone in the treatment of HBeAg-positive chronic hepatitis B. Indian J Gastroenterol 2006, 25:71-73.
13. Janssen H.L., van Zonneveld M., Senturk H., Zeuzem S., Akarca U.S., Cakaloglu Y., et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005, 365:123-129.
14. Yalcin K., Degertekin H., Yildiz F., Celik Y. Comparison of 12-month courses of interferon-alpha-2b-lamivudine combination therapy and interferon-alpha-2b monotherapy among patients with untreated chronic hepatitis B. Clin Infect Dis 2003, 36:1516-1522.
15. Barbaro G., Zechini F., Pellicelli A.M., Francavilla R., Scotto G., Bacca D., et al. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. J Hepatol 2001, 35:406-411.
16. Chan H.L., Leung N.W., Hui A.Y., Wong V.W., Liew C.T., Chim A.M., et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005, 142:240-250.
17. Lau G.K., Piratvisuth T., Luo K.X., Marcellin P., Thongsawat S., Cooksley G., et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005, 352:2682-2695.
18. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003, 348:800-807.
19. Hou J., Yin Y.K., Xu D., Tan D., Niu J., Zhou X., et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology 2008, 47:447-454.
20. Lai C.L., Gane E., Liaw Y.F., Hsu C.W., Thongsawat S., Wang Y., et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007, 357:2576-2588.
21. Piccolo P., Lenci I., Demelia L., Bandiera F., Piras M.R., Antonucci G., et al. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther 2009, 14:1165-1174.
22. Kaymakoglu S., Oguz D., Gur G., Gurel S., Tankurt E., Ersoz G., et al. Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B. Antimicrob Agents Chemother 2007, 51:3020-3022.
23. Lai C.L., Shouval D., Lok A.S., Chang T.T., Cheinquer H., Goodman Z., et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006, 354:1011-1020.
24. Marcellin P., Lau G.K., Bonino F., Farci P., Hadziyannis S., Jin R., et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004, 351:1206-1217.
25. Economou M., Manolakopoulos S., Trikalinos T.A., Filis S., Bethanis S., Tzourmakliotis D., et al. Interferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B. World J Gastroenterol 2005, 11:5882-5887.
26. Papadopoulos V.P., Chrysagis D.N., Protopapas A.N., Goulis I.G., Dimitriadis G.T., Mimidis K.P. Peginterferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomised study. Med Sci Monit 2009, 15:CR56-CR61.
27. Sung J.J., Lai J.Y., Zeuzem S., Chow W.C., Heathcote E.J., Perrillo R.P., et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008, 48:728-735.
28. Yurdaydin C., Bozkaya H., Cetinkaya H., Sahin T., Karaoguz D., Toruner M., et al. Lamivudine vs lamivudine and interferon combination treatment of HBeAg(-) chronic hepatitis B. J Viral Hepat 2005, 12:262-268.
29. Chan H.L., Heathcote E.J., Marcellin P., Lai C.L., Cho M., Moon Y.M., et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007, 147:745-754.
30. Levy A.R., Kowdley K.V., Iloeje U., Tafesse E., Mukherjee J., Gish R., et al. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health 2008, 11:527-538.
31. Chen C.J., Yang H.I., Iloeje U.H. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 2009, 49(Suppl. 5):S72-S84.
32. Iloeje U.H., Yang H.I., Su J., Jen C.L., You S.L., Chen C.J. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130:678-686.
33. Kanwal F., Gralnek I.M., Martin P., Dulai G.S., Farid M., Spiegel B.M. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 2005, 142:821-831.
34. Spackman D.E., Veenstra D.L. A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B. Pharmacoeconomics 2008, 26:937-949.
35. Veenstra D.L., Spackman D.E., Di Bisceglie A., Kowdley K.V., Gish R.G. Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis. Aliment Pharmacol Ther 2008, 27:1240-1252.
36. Veenstra D.L., Sullivan S.D., Lai M.Y., Lee C.M., Tsai C.M., Patel K.K. HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan. Value Health 2008, 11:131-138.
37. Wu B., Li T., Chen H., Shen J. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis. Value Health 2010, 13:592-600.
38. Chen J.D., Yang H.I., Iloeje U.H., You S.L., Lu S.N., Wang L.Y., et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 2010, 138:1747-1754.
39. Castelo A., Pessoa M.G., Barreto T.C., Alves M.R., Araujo D.V. Cost estimates of chronic hepatitis B virus for the Brazilian unified health system in 2005. Rev Assoc Med Bras 2007, 53:486-491.
40. Leung N. Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues. Liver Int 2011, 31(Suppl 1):85-89.
41. Suzuki F., Toyoda J., Katano Y., Sata M., Moriyama M., Imazeki F., et al. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients. J Gastroenterol Hepatol 2008, 23:1320-1326.
42. Dan Y.Y., Aung M.O., Lim S.G. The economics of treating chronic hepatitis B in Asia. Hepatol Int 2008, 2:284-295.
43. Costa A.M., Li G., Nita M.E., Araujo E.S. Cost-effectiveness of entecavir versus lamivudine for the suppression of viral replication in chronic hepatitis B patients in Brazil. Braz J Infect Dis 2008, 12:368-373.
44. Buti M., Brosa M., Casado M.A., Rueda M., Esteban R. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol 2009, 51:640-646.
45. Vanagas G., Padaiga Z., Mickeviciene A. Cost-effectiveness and cost-utility of the treatment of chronic hepatitis B with peginterferon alfa-2a, interferon alfa, and lamivudine in Lithuania. Medicina (Kaunas) 2010, 46:835-842.